Evidence map›Paper›PMID 35480112›Full record

ArticleFrontiers in oncology2022

CpG Site-Specific Methylation-Modulated Divergent Expression of

Shuye Lin, Hanli Xu, Mengdi Pang, Xiaomeng Zhou, Yuanming Pan, Lishu Zhang, Xin Guan, Xiaoyue Wang, Bonan Lin, Rongmeng Tian and 11 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 2 countries.

Shuye LinCancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Hanli XuCollege of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing, China.
Mengdi PangCollege of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing, China.
Xiaomeng ZhouCollege of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing, China.
Yuanming PanCancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Lishu ZhangCollege of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing, China.
Xin GuanCollege of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing, China.
Xiaoyue WangCollege of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing, China.
Bonan LinCollege of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing, China.
Rongmeng TianCollege of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing, China.
Keqiang ChenLaboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, Frederick, MD, United States.
Xiaochen ZhangCollege of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing, China.
Zijiang YangCollege of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing, China.
Fengmin JiCollege of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing, China.
Yingying HuangChinese Academy of Sciences (CAS) Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
Wu WeiChinese Academy of Sciences (CAS) Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
Wanghua GongBasic Research Program, Leidos Biomedical Research, Inc., Frederick, MD, United States.
Jianke RenChinese Academy of Sciences (CAS) Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
Ji Ming WangLaboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, Frederick, MD, United States.
Mingzhou GuoDepartment of Gastroenterology and Hepatology, Chinese People's Liberation Army of China (PLA) General Hospital, Beijing, China.
Jiaqiang HuangCancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Beijing Jiaotong University · CNBeijing Chest Hospital · CNChinese People's Liberation Army · CNShanghai Institute of Nutrition and Health · CNCapital Medical University · CNCenter for Cancer Research · USLeidos (United States) · USNational Cancer Institute · USUniversity of Chinese Academy of Sciences · CN

Funding

The Role of Cellular Receptors Involved in Inflammation and Tumor ProgressionZIABC010015 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, JI MING · 2009 to 2023
$6.3M
6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most lethal human tumors with extensive intratumor heterogeneity (ITH). Serine protease 3 (PRSS3) is an indispensable member of the trypsin family and has been implicated in the pathogenesis of several malignancies, including HCC. However, the paradoxical effects of Methods: The expression and DNA methylation of Results: Conclusions: These results provide the first evidence for the transcriptional and functional characterization of

Indexed as

biomarkerCpG methylationepigeneticshepatocellular carcinomaintratumor heterogeneityliver cancerPRSS3transcript variant

Identifiers

PMID35480112
PMCPMC9035874
OpenAlexW4223456941

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.